Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (161-170 of 280) with videos related to

Pageof 28
Sort By:
Cancer Chemotherapy and Pharmacology|March 26, 2014
A phase I study of oral ixabepilone in patients with advanced solid tumorsJohn F Deeken, John L Marshall, Michael J Pishvaian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational TrialsStacy S Shord, Cong Chen, Jin Y Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomesJoel M Reid, Denise L Walker, Jennifer K Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancerJ L Blum, S E Jones, A U Buzdar, et al.
Cancer Chemotherapy and Pharmacology|December 9, 2010
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsElisabeth I Heath, George R Blumenschein, Roger B Cohen, et al.
Investigational New Drugs|December 6, 2014
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumorsMark A Dickson, Michael S Gordon, Gerald Edelman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2012
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric studyF Zanaboni, B Grijuela, S Giudici, et al.
Investigational New Drugs|September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabineLaura W Goff, Al B Benson, Patricia M LoRusso, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerManish Gupta, Bei Wang, Timothy J Carrothers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumorsA W Tolcher, K P Papadopoulos, A Patnaik, et al.
Pageof 28

Showing results (161-170 of 280) with videos related to

Sort By:
Pageof 28
Cancer Chemotherapy and Pharmacology|March 26, 2014
A phase I study of oral ixabepilone in patients with advanced solid tumorsJohn F Deeken, John L Marshall, Michael J Pishvaian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational TrialsStacy S Shord, Cong Chen, Jin Y Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomesJoel M Reid, Denise L Walker, Jennifer K Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancerJ L Blum, S E Jones, A U Buzdar, et al.
Cancer Chemotherapy and Pharmacology|December 9, 2010
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsElisabeth I Heath, George R Blumenschein, Roger B Cohen, et al.
Investigational New Drugs|December 6, 2014
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumorsMark A Dickson, Michael S Gordon, Gerald Edelman, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2012
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric studyF Zanaboni, B Grijuela, S Giudici, et al.
Investigational New Drugs|September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabineLaura W Goff, Al B Benson, Patricia M LoRusso, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerManish Gupta, Bei Wang, Timothy J Carrothers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumorsA W Tolcher, K P Papadopoulos, A Patnaik, et al.
Pageof 28